



Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1

Protocol-ID: 817 V2.1 (Mini), BORT1.3/DRTM16/DEXA(20/20), MM, C1

Indication(s)

- Multiple Myeloma; ICD-10 C90.-, C90.0-

Links

- Daratumumab: Risiko der Reaktivierung von Hepatitis B [[BfARM Risikoinf. Rote Hand etc.](#)]



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 15.04.2021